Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer.
Journal
Genes and immunity
ISSN: 1476-5470
Titre abrégé: Genes Immun
Pays: England
ID NLM: 100953417
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
11
05
2023
accepted:
04
09
2023
revised:
30
08
2023
medline:
23
10
2023
pubmed:
28
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
There is an urgent need for new and better biomarker modalities to estimate the risk of recurrence within the luminal-like breast cancer (BC) population. Molecular diagnostic tests used in the clinic lack accuracy in identifying patients with early luminal BC who are likely to develop metastases. This study provides proof of concept that various liquid biopsy read-outs could serve as valuable candidates to build a multi-modal biomarker model distinguishing, already at diagnosis, between early metastasizing and non-metastasizing patients. All these blood biomarkers (chemokines, microRNAs, leukemia inhibitory factor, osteopontin, and serum-induced functional myeloid signaling responses) can be measured in baseline plasma/serum samples and could be added to the existing prognostic factors to improve risk stratification and more patient-tailored treatment in early luminal BC.
Identifiants
pubmed: 37759086
doi: 10.1038/s41435-023-00220-z
pii: 10.1038/s41435-023-00220-z
pmc: PMC10575765
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
270-279Informations de copyright
© 2023. The Author(s).
Références
Bediaga NG, Beristain E, Calvo B, Viguri MA, Gutierrez-Corres B, Rezola R, et al. Luminal B breast cancer subtype displays a dicotomic epigenetic pattern. Springerplus 2016;5:623.
pubmed: 27330889
pmcid: 4870487
doi: 10.1186/s40064-016-2235-0
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32:2794–803.
pubmed: 25049332
doi: 10.1200/JCO.2013.54.1870
Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget 2016;7:65024–33.
pubmed: 27542253
pmcid: 5323135
doi: 10.18632/oncotarget.11344
Lonning PE. Breast cancer prognostication and prediction: are we making progress?. Ann Oncol. 2007;18:viii3–7.
pubmed: 17890212
doi: 10.1093/annonc/mdm260
Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606–16.
pubmed: 15561805
doi: 10.1634/theoncologist.9-6-606
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N. Engl J Med. 2018;379:111–21.
pubmed: 29860917
pmcid: 6172658
doi: 10.1056/NEJMoa1804710
Audeh W, Blumencranz L, Kling H, Trivedi H, Srkalovic G. Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial. Acta Med Acad. 2019;48:18–34.
pubmed: 31264430
doi: 10.5644/ama2006-124.239
Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009;69:7495–8.
pubmed: 19773429
pmcid: 2756311
doi: 10.1158/0008-5472.CAN-09-2111
Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Perez-Plasencia C, Del Moral-Hernandez O, Castaneda-Ortiz EJ, et al. MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis. Int J Mol Sci. 2012;13:1347–79.
pubmed: 22408395
pmcid: 3291964
doi: 10.3390/ijms13021347
Mandujano-Tinoco EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V. New emerging roles of microRNAs in breast cancer. Breast Cancer Res Treat. 2018;171:247–59.
pubmed: 29948402
doi: 10.1007/s10549-018-4850-7
Petri BJ, Klinge CM. Regulation of breast cancer metastasis signaling by miRNAs. Cancer Metastasis Rev. 2020;39:837–86.
pubmed: 32577859
pmcid: 7487050
doi: 10.1007/s10555-020-09905-7
Marcuzzi E, Angioni R, Molon B, Cali B. Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization. Int J Mol Sci. 2018;20.
Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2:1125–31.
pubmed: 25480554
pmcid: 4258879
doi: 10.1158/2326-6066.CIR-14-0160
Ali S, Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev. 2007;26:401–20.
pubmed: 17717637
pmcid: 2668792
doi: 10.1007/s10555-007-9073-z
Clemente N, Raineri D, Cappellano G, Boggio E, Favero F, Soluri MF, et al. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. J Immunol Res. 2016;2016:7675437.
pubmed: 28097158
pmcid: 5206443
doi: 10.1155/2016/7675437
Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 1997;3:605–11.
pubmed: 9815727
Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17–24.
pubmed: 30003880
doi: 10.1016/j.clinbiochem.2018.07.003
Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C, et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget 2014;5:788–801.
pubmed: 24553191
pmcid: 3996668
doi: 10.18632/oncotarget.1772
Shin JE, Park SH, Jang YK. Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer. Mol Cells. 2011;31:181–9.
pubmed: 21191816
pmcid: 3932684
doi: 10.1007/s10059-011-0020-z
Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18:261–79.
pubmed: 33469195
pmcid: 8978805
doi: 10.1038/s41571-020-00459-9
Sprooten J, Coosemans A, Garg AD. A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. Oncoimmunology 2022;11:2024692.
pubmed: 35036075
pmcid: 8757472
doi: 10.1080/2162402X.2021.2024692
Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters R, et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer. 2021;9.
Vaes RDW, Reynders K, Sprooten J, Nevola KT, Rouschop KMA, Vooijs M, et al. Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. Cancers (Basel). 2021;13:6259.
pubmed: 34944879
doi: 10.3390/cancers13246259
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144:545–63.
pubmed: 31928354
doi: 10.5858/arpa.2019-0904-SA
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105–22.
pubmed: 29846122
doi: 10.1200/JCO.2018.77.8738
Pinatel EM, Orso F, Penna E, Cimino D, Elia AR, Circosta P, et al. miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. PLoS One. 2014;9:e84859.
pubmed: 24400121
pmcid: 3882278
doi: 10.1371/journal.pone.0084859
Wang DD, Chen X, Yu DD, Yang SJ, Shen HY, Sha HH, et al. miR-197: A novel biomarker for cancers. Gene 2016;591:313–9.
pubmed: 27320730
doi: 10.1016/j.gene.2016.06.035
de Melo Maia B, Rodrigues IS, Akagi EM, Soares do Amaral N, Ling H, Monroig P, et al. MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression. Oncotarget 2016;7:49217–31.
pubmed: 27359057
pmcid: 5226502
doi: 10.18632/oncotarget.10247
Li M, Liu L, Zang W, Wang Y, Du Y, Chen X, et al. miR‑365 overexpression promotes cell proliferation and invasion by targeting ADAMTS-1 in breast cancer. Int J Oncol. 2015;47:296–302.
pubmed: 25998153
doi: 10.3892/ijo.2015.3015
Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M, Iwase H. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence. Oncotarget 2017;8:69934–44.
pubmed: 29050253
pmcid: 5642528
doi: 10.18632/oncotarget.19482
Luo Z, Zheng Y, Zhang W. Pleiotropic functions of miR107 in cancer networks. Onco Targets Ther. 2018;11:4113–24.
pubmed: 30140157
pmcid: 6054759
doi: 10.2147/OTT.S151236
Yang C, Dou R, Yin T, Ding J. MiRNA-106b-5p in human cancers: diverse functions and promising biomarker. Biomed Pharmacother. 2020;127:110211.
pubmed: 32422566
doi: 10.1016/j.biopha.2020.110211
Yin Y, Cai J, Meng F, Sui C, Jiang Y. MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55. Cancer Biol Ther. 2018;19:306–15.
pubmed: 29561704
pmcid: 5902245
doi: 10.1080/15384047.2017.1416934
Deng S, Li X, Niu Y, Zhu S, Jin Y, Deng S, et al. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Oncotarget 2015;6:39661–75.
pubmed: 26498682
pmcid: 4741853
doi: 10.18632/oncotarget.5350
Wang R, Tian S, Wang HB, Chu DP, Cao JL, Xia HF, et al. MiR-185 is involved in human breast carcinogenesis by targeting Vegfa. FEBS Lett. 2014;588:4438–47.
pubmed: 25448984
doi: 10.1016/j.febslet.2014.09.045
Bottani M, Banfi G, Lombardi G. Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma. J Clin Med. 2019;8:1661.
pubmed: 31614612
pmcid: 6833074
doi: 10.3390/jcm8101661
Elghoroury EA, ElDine HG, Kamel SA, Abdelrahman AH, Mohammed A, Kamel MM, et al. Evaluation of miRNA-21 and miRNA Let-7 as Prognostic Markers in Patients With Breast Cancer. Clin Breast Cancer. 2018;18:e721–e6.
pubmed: 29292183
doi: 10.1016/j.clbc.2017.11.022
Viswanadhapalli S, Dileep KV, Zhang KYJ, Nair HB, Vadlamudi RK. Targeting LIF/LIFR signaling in cancer. Genes Dis. 2022;9:973–80.
pubmed: 35685476
doi: 10.1016/j.gendis.2021.04.003
Xu F, Li H, Hu C LIFR-AS1 modulates Sufu to inhibit cell proliferation and migration by miR-197-3p in breast cancer. Biosci Rep. 2019;39.
Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, et al. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene 2019;38:2814–29.
pubmed: 30546090
doi: 10.1038/s41388-018-0624-2
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301–9.
pubmed: 25344738
doi: 10.1038/nm.3708
Slaney CY, Moller A, Hertzog PJ, Parker BS. The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. Oncoimmunology 2013;2:e22339.
pubmed: 23482870
pmcid: 3583915
doi: 10.4161/onci.22339
Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA. 2009;106:9010–5.
pubmed: 19451644
pmcid: 2690021
doi: 10.1073/pnas.0901329106
Wang L, Simons DL, Lu X, Tu TY, Avalos C, Chang AY, et al. Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine 2020;52:102631.
pubmed: 31981982
pmcid: 6992943
doi: 10.1016/j.ebiom.2020.102631
Yamazaki T, Kirchmair A, Sato A, Buque A, Rybstein M, Petroni G, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol. 2020;21:1160–71.
pubmed: 32747819
doi: 10.1038/s41590-020-0751-0
Rodriguez-Ruiz ME, Buque A, Hensler M, Chen J, Bloy N, Petroni G, et al. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology 2019;8:e1655964.
pubmed: 31646105
pmcid: 6791460
doi: 10.1080/2162402X.2019.1655964
Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis. Oncoimmunology 2016;5:e1069938.
pubmed: 27057433
doi: 10.1080/2162402X.2015.1069938
Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 2018;9:847.
pubmed: 29780381
pmcid: 5945880
doi: 10.3389/fimmu.2018.00847